Transcatheter aortic-valve replacement for inoperable severe aortic stenosis.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is the recommended therapy for patients with severe aortic stenosis who are not suitable candidates for surgery. The outcomes beyond 1 year in such patients are not known. METHODS: We randomly assigned patients to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty). Data on 2-year outcomes were analyzed. RESULTS: A total of 358 patients underwent randomization at 21 centers. The rates of death at 2 years were 43.3% in the TAVR group and 68.0% in the standard-therapy group (P<0.001), and the corresponding rates of cardiac death were 31.0% and 62.4% (P<0.001). The survival advantage associated with TAVR that was seen at 1 year remained significant among patients who survived beyond the first year (hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.92; P=0.02 with the use of the log-rank test). The rate of stroke was higher after TAVR than with standard therapy (13.8% vs. 5.5%, P=0.01), owing, in the first 30 days, to the occurrence of more ischemic events in the TAVR group (6.7% vs. 1.7%, P=0.02) and, beyond 30 days, to the occurrence of more hemorrhagic strokes in the TAVR group (2.2% vs. 0.6%, P=0.16). At 2 years, the rate of rehospitalization was 35.0% in the TAVR group and 72.5% in the standard-therapy group (P<0.001). TAVR, as compared with standard therapy, was also associated with improved functional status (P<0.001). The data suggest that the mortality benefit after TAVR may be limited to patients who do not have extensive coexisting conditions. Echocardiographic analysis showed a sustained increase in aortic-valve area and a decrease in aortic-valve gradient, with no worsening of paravalvular aortic regurgitation. CONCLUSIONS: Among appropriately selected patients with severe aortic stenosis who were not suitable candidates for surgery, TAVR reduced the rates of death and hospitalization, with a decrease in symptoms and an improvement in valve hemodynamics that were sustained at 2 years of follow-up. The presence of extensive coexisting conditions may attenuate the survival benefit of TAVR. (Funded by Edwards Lifesciences; number, NCT00530894.).

Full Text

Duke Authors

Cited Authors

  • Makkar, RR; Fontana, GP; Jilaihawi, H; Kapadia, S; Pichard, AD; Douglas, PS; Thourani, VH; Babaliaros, VC; Webb, JG; Herrmann, HC; Bavaria, JE; Kodali, S; Brown, DL; Bowers, B; Dewey, TM; Svensson, LG; Tuzcu, M; Moses, JW; Williams, MR; Siegel, RJ; Akin, JJ; Anderson, WN; Pocock, S; Smith, CR; Leon, MB; PARTNER Trial Investigators,

Published Date

  • May 3, 2012

Published In

Volume / Issue

  • 366 / 18

Start / End Page

  • 1696 - 1704

PubMed ID

  • 22443478

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1202277


  • eng

Conference Location

  • United States